New York State Common Retirement Fund Has $106.84 Million Stock Position in Bristol Myers Squibb Company $BMY

New York State Common Retirement Fund cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,368,976 shares of the biopharmaceutical company’s stock after selling 146,360 shares during the quarter. New York State Common Retirement Fund owned about 0.12% of Bristol Myers Squibb worth $106,841,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Trifecta Capital Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the second quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its stake in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the period. REAP Financial Group LLC grew its stake in shares of Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 428 shares during the period. Finally, DHJJ Financial Advisors Ltd. grew its position in Bristol Myers Squibb by 51.9% in the second quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 267 shares during the period. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

BMY has been the topic of several recent analyst reports. Citigroup restated a “neutral” rating and issued a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Tuesday. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. HSBC reissued a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, Wells Fargo & Company raised their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $57.43.

Bristol Myers Squibb Trading Down 0.7%

BMY stock opened at $54.25 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a market cap of $110.43 billion, a P/E ratio of 18.33, a PEG ratio of 0.17 and a beta of 0.29. The business has a fifty day moving average of $53.24 and a 200-day moving average of $48.59.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.80 earnings per share. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. Bristol Myers Squibb’s payout ratio is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.